Similar articles

• Amantadine in the treatment of Creutzfeldt-Jakob disease.

  Braham J. Braham J. Arch Neurol. 1984 Jun;41(6):585-6. Arch Neurol. 1984. PMID: 6372758 No abstract available.
• [A new variant of Creutzfeldt-Jakob disease. Do we want development of a new epidemic?].

  Sande R, Tysnes OB. Sande R, et al. Tidsskr Nor Laegeforen. 1997 Jan 30;117(3):384-8. Tidsskr Nor Laegeforen. 1997. PMID: 9064863 Review. Norwegian.
• Creutzfeldt-Jakob disease with focal onset unsuccessfully treated with amantadine.

  Ratcliffe J, Rittman A, Wolf S, Verity MA. Ratcliffe J, et al. Bull Los Angeles Neurol Soc. 1975 Jan;40(1):18-20. Bull Los Angeles Neurol Soc. 1975. PMID: 1097004 No abstract available.
• [Amantadine in Creutzfeldt-Jakob disease. Review of the literature and case contribution].

  Neri G, Figà-Talamanca L, Di Battista GC, Lo Russo F. Neri G, et al. Riv Neurobiol. 1984 Jan-Mar;30(1):47-56. Riv Neurobiol. 1984. PMID: 6399949 Italian. No abstract available.
• Emerging pharmacotherapies for Creutzfeldt-Jakob disease.

  Korth C, Peters PJ. Korth C, et al. Arch Neurol. 2006 Apr;63(4):497-501. doi: 10.1001/archneur.63.4.497. Arch Neurol. 2006. PMID: 16606761 Review.